/* Via Victoria: hard lock to the intended light colour palette on mobile browsers. */
Leukaemia, explained simply / Episode 09

Besponza (inotuzumab)

A short illustrated guide from our family experience. Swipe sideways on your phone to see all six slides.

English overview

Inotuzumab ozogamicin (Besponza) is an antibody–drug conjugate targeting CD22-positive cells. Its use depends on the individual diagnosis and specialist treatment plan.

The six illustrated slides below retain their original Slovak text. This English overview is informational and is not a substitute for medical advice. Individual diagnosis and treatment decisions must be made by a qualified medical team.

1 / 6
Besponza (inotuzumab) — slide 1 of 6, original Slovak text
Besponza (inotuzumab) — slide 2 of 6, original Slovak text
Besponza (inotuzumab) — slide 3 of 6, original Slovak text
Besponza (inotuzumab) — slide 4 of 6, original Slovak text
Besponza (inotuzumab) — slide 5 of 6, original Slovak text
Besponza (inotuzumab) — slide 6 of 6, original Slovak text
← 08 / Blinatumomab